Member Info for Sisu

Users will then likely fill in a quick form, usability out of 100 etc.

Scardey_cat will probably be kicked out trying to rummage through the boxes of them screaming "it's us" whilst bowing to the magical harnessing power of the super-Affimers he is graced to be so close with.

Very hard to do Innova's test correctly when the IFU say to tickle some bogeys yet the correct collection method is the lower part of your brain!

AS is big on the Socio-Economic side (atleast he mentions it a fair bit) and we know this is a huge thorn in the side of positive publicity if the specificity is poor. Joe Public (understandably) don't want to miss out on their lives/livelihoods on something falsely telling them they have the virus.

Good to see the PR push is getting traction. They just need a good UK-made test in public domain.

Here comes the PR push. Oh look

"And they’re incredibly accurate. ‘When done correctly, the tests are at least 99.9 per cent specific, which means that the risk of false positives is extremely low – less than one in a thousand,’ says Dr Khan. "

Who knows a 99+% specific test? Step in Avacta.

Out of a total of 102 negative samples tested with the lateral flow device, the test correctly identified 101 as negative, giving a clinical specificity of 99.0%.

P.s. Mologic/ODX is 97.8% specific at 95% CI. Max read of 99.3%.

Fantastic.

Can't disagree with someone else's beliefs/thoughts but one question Si, why have the DPS not began to announce tenders, press began their positive LFT-related news surge, manufacturers not announced which test they are making for UK Gov? Mologic/ODX test is there, it's ready, it's use-by date is ticking daily - get it out to the public!?

I believe also a next-gen LFT (using Affimers) will be in pipeline, why would it not be Affimers. Superiority is in all scientific reports and also in AVCT's clinical validation.

Good luck to ODX, sure the price will steadily increase LT - but risk perceived for me is next to none (unless DHSC don't pay up!), so upside is also limited. Capacity is there. AVCT will sell all they can make, I can assure you of that, and also all that others can make for them (within white-label tests).

Appreciate the response Simon, IMO TT won't take 2-3 months. The casing being used is Mologic's, GAD have the end-to-end process in place so it is a rather simple process and it will also be in process currently.

They won't be handed instructions and have to get going from that date. TT is a very broad spectrum of things encapsulated in an over-used term, you may have reasoning to your 2-3 months but I don't think it will take that long if it's not the Mologic test.

I Agree re Mologic, they have huge tie ins with Wellcome Trust and the Gates Foundation - GAD shows that - AVCT are tied in with GAD.

A genuine question and happy for it to be answered by ODX investors (we know they frequent!) - what is the 'big' news ODX await for? Consistent comments on Twitter/LSE about awaiting for the big news and re-rate, I assume it's related to the Gov announcing the Sovereign test? We know they are producing x amount of tests for the Government regardless of which test. I don't see the risk so I don't see as much of an upside?

Not trying to shoot anything down just understanding the risk SP-wise attached to AVCT ST is probably aligned to UK Gov, due to the expectation built (and knowing this expectation will be partly built into current SP manufacturing figures dependant). ODX don't have such a risk in that regard, where does the upside live, intricacies of the contract I assume?

FindDx report shows 20 of the 665 tests carried out on ODX/Mologic test were using a Nasal Mid-Turbinate (NMT) testing method... interesting! A random c.3% as a different testing method (coincidentally likely more efficient of a method, also) to the IFU. Anyone have any logical reason; other than the potential for preferential results, in comparison to lower nasal) in this small set of data?

Likely batch verifications (against product spec.). End of April was noted. It's getting real close guys...

https://twitter.com/mologic/status/1387404221985734657?s=19

Cheers Simon, great analysis. I have just bought a few thousand more shares.

Unfortunately, I can't help you if you're disappointed with a one year turn-around time for the best-in-market LFT test during a pandemic with no direct company experience in the field previous to the pandemic.

Just take a back step, best in class test (I say this until I see something that shows me otherwise!) headed by little old Avacta. Novo Nordisk (to name one of the biggest fish) have a MCap of just shy of 171Billion USD. AVCT's is 843m USD. If AVCT have taken so long then why aren't there already much better tests in market than we are about to release within weeks?

Gkb, you also said "Yes the DeepVerge test collaboration, I know it's not their test but why not mention what's happening, or is it not worth mentioning? What's happening with that evaluation up at Aberdeen? Last I heard DeepVerge were using Aptamers anyway."

I below quote you a DeepVerge RNS from 17th March 2021

"In addition, under the clinical trial supervision of the Royal College of Surgeons, Ireland, 40 subjects, 16 of which were independently confirmed as COVID19 positive with PCR[iii] tests, provided breath samples that were tested on the Microtox® BT nano-optofluidic chip surface with Affimer® reagents ("Avacta Group")[iv] and Optimers ("Aptamer Group")[v] together the ("Binding Agents")."

I'm happy to engage in such conversations as I love to learn as much as possible of the companies I am involved in, I'd advise you doing so too! Anyway, I wish you all the best with your investment here. It's put a lot of people in to a greatly profitable position, I hope you are also one of those. Life changing, hopefully. :)

Gkb, twice you've said things and I've counterargued them and you've then agreed with me by saying you are aware of them and gone off on a sideways tangent? You said DeepVerge only used Aptamers and then knew that they also used Affimers?

If in doubt just take a look at the Innova instructions, the directions show you to brain-tickle.

P.S. Five trading days until May, how exciting to know we have the best product (also accounting for all variables including cost, ease of manufacturing, s/s, collection method etc.) coming to market that has a near limitless requirement for these tests. Also about to cement Affimers as a fantastic working tech, lock-in a place in future diagnostic approaches to pandemics and whilst we're at it, globally advertise them/the company too. Think about the money and resource companies like Roche have, and this test has proven itself to blow theirs out of the water!

Gkb.

https://www.england.nhs.uk/coronavirus/wp-content/uploads/sites/52/2020/11/C0873_i_SOP_LFD-rollout-for-asymptomatic-staff-testing_phase-2-trusts-v1.1_16-nov20.pdf

Page 3 -" The manufacturer’s instructions for use (IFU) are included in the box and are detailed and very technical. These do not need to be followed as NHS staff will use the test in a slightly different way, which has been agreed with experts, discussed with MHRA, and the manufacturer informed. This is particularly in relation to use of the test for asymptomatic people, self-administration of the test, and the use of nasal swab inside the lower part of both nostrils. The rest of the process (ie the way the test is performed, and the results are interpreted) is the same as set out in the manufacturer’s instructions"

https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/943187/S0925_Innova_Lateral_Flow_SARS-CoV-2_Antigen_test_accuracy.pdf

48.89% sensitivity. Yuck

Freudian slip if I've ever heard one.

Hi gkb, DeepVerges test utilises both Aptamers and Affimers in collaboration.

In regard to DHSC home testing of Innova, Innova was validated as a brain-tickler - there are lots of reports out there showing how when used as AN (as AVCT are utilising) the S/S is significantly less than reported. It was designed and tested as a brain-tickler, UK Gov wanted to keep the quantity high so took the decision to allow a very ineffective test, within its unverified collection method, to be utilised. There is a higher quantity of the viral load in the brain-tickler region than there is AP, wouldn't surprise me if we saw 100%/100% s/s with AVCT using that testing method and then passing it through underhand as AP.

https://presentations.investormeetcompany.com/investor-meet-company/AVACTA-GROUP-PLC-Full-year-12-month-results-ending-on-31st-Dec-2020?bmid=1659dd036676

https://twitter.com/avacta/status/1385531622351593474

The good stuff is from 00:01s to 01h01m! :)

If NCYT are partnering with someone, their s/s will very unlikely be market leading especially without the amount of time tweaking required to refine the s/s. Good luck to them whatever they make, I'm sure it'll sell.

Although what a great plot twist if AffiRx's first customer is NCYT and they're using our magic beans for their saliva test :-) We will harpoon a few big fish that want a slice of the LFT pie I am sure, what better way than to utilise the most specific of technologies (oh and 100% sensitive to infectious level viral loads, too!).

I've genuinely become apathetic towards the SP. I will re-tune in to my emotion of it when I feel some of the potential has been realised. That will be when Affimers are working their magic after millions of people have shoved a swab up their nose, and re-agents are being distributed around the world.

Vaccine-gate caused the SP to drop to below 100p, of which the SP is currently 2.5x of, despite huge reports stating how critical testing will be and will need to work along side vaccination. AIM is very irrational, the more it's understood the easier it is to set your position and only review when you feel it is best time to do so for any given reason.

I listened to every word and picked up on no head-scratching comments that may be concerned. Just the fact LFT works, very well, demand is absolutely massive and AVCT are directly aware of that. 5M p/m as a low end figure of manufacturing capacity in UK is not concerning for me, given EU and RoW were signalled as potential requirements also. We also wouldn't be hinted at 30m if it wasn't a reasonable goal.

Great presentation, btw.

All but seemingly confirmed UK Gov involvement by iterating he can't put concrete figure on the upper end of manufacturing capacity due to ongoing nature of Government investment for (UK Capacity wise)- in direct relation to our manufacturing capacity.

Oooh this is a good presentation!